ImmunityBio, Inc.
- IBRX
- NASDAQ
- Biotechnology
- Immuno-oncology/Cell Therapy
- Cancer & Infectious Disease Vaccines
$8.63
Today −5.94%Quote Oct 19, 2026, 05:00 PM UTC
+8.51%over the last month
Max drawdown −12.7%From 1-month high −12.7%3 months +22.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About ImmunityBio
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases.
Where the money comes from
Q2 2026 revenue $51.2M
- Product$50.7M98.9%
- Product and Service, Other$568,0001.1%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
688
Founded
2014
Market value
$9.15B
Quote Oct 19
Floor
$8.29
4.0% below price
Resistance
$8.74
1.2% above price
Price vs analyst targets
5 analysts
Lowest target
$12.00Highest target
$16.00
$12.00Highest target
$16.00
- Price $8.63
- Average target $14.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 62% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about IBRXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free